Can the Seattle Heart Failure Model Be Used to Risk-stratify Heart Failure Patients for Potential Left Ventricular Assist Device Therapy? Wayne C. Levy,

Slides:

Advertisements

Similar presentations

Dual-site right ventricular and left ventricular pacing in a patient with left ventricular systolic dysfunction and atrial fibrillation using a standard.

Advertisements

Comparative cost-effectiveness of the HeartWare versus HeartMate II left ventricular assist devices used in the United Kingdom National Health Service.

Systolic blood pressure on discharge after left ventricular assist device insertion is associated with subsequent stroke Michael E. Nassif, MD, Anjan Tibrewala,

Sixth INTERMACS annual report: A 10,000-patient database James K. Kirklin, MD, David C. Naftel, PhD, Francis D. Pagani, MD, PhD, Robert L. Kormos, MD,

Janet T. Lee, MD, Rosemary F. Kelly, MD, Marshall I

Evan P. Kransdorf, MD, PhD, Michelle M. Kittleson, MD, PhD, Jignesh K

Identifying patients for advanced heart failure therapy by screening patients with cardiac resynchronization therapy or implantable cardioverter-defibrillator:

Utility of the Seattle Heart Failure Model in patients with cardiac resynchronization therapy and implantable cardioverter defibrillator referred for.

Impact of aortic valve closure on adverse events and outcomes with the HeartWare ventricular assist device David Dobarro, MD, Marian Urban, MD, Karen.

James K. Kirklin, MD, Francis D. Pagani, MD, PhD, Robert L

Incremental and independent value of cardiopulmonary exercise test measures and the Seattle Heart Failure Model for prediction of risk in patients with.

Jennifer A. Cowger, MD, Matthew A

The Registry of the International Society for Heart and Lung Transplantation: Twenty- seventh official adult heart transplant report—2010 Josef Stehlik,

The Journal of Heart and Lung Transplantation

Impact of initial Norwood shunt type on young hypoplastic left heart syndrome patients listed for heart transplant: A multi-institutional study Waldemar.

Low vitamin D levels are associated with increased rejection and infections after lung transplantation Erin M. Lowery, MD, Bradford Bemiss, MD, Thomas.

Left ventricular assist devices decrease fixed pulmonary hypertension in cardiac transplant candidates Daniel Zimpfer, MD, Philipp Zrunek, MS, Wilfried.

Boot Camp for Ventricular Assist Device Patient Recovery beyond Medical Management E.A. Hamad, V. Devlin, K. McDonnell, N. Robinson, M. Welsh, E. Kerr,

Limitations of right heart catheterization in the diagnosis and risk stratification of patients with pulmonary hypertension related to left heart disease:

Pre-operative mortality risk assessment in patients with continuous-flow left ventricular assist devices: Application of the HeartMate II risk score

The Registry of the International Society for Heart and Lung Transplantation: Thirty-first Official Adult Heart Transplant Report—2014; Focus Theme: Retransplantation

Outcomes in highly sensitized pediatric heart transplant patients using current management strategies Alfred Asante-Korang, MD, Ernest K. Amankwah, PhD,

Two decades of pediatric lung transplant in the United States: Have we improved? Farhan Zafar, MD, Jeffrey S. Heinle, MD, Marc G. Schecter, MD, Joseph.

Severe Mitral Regurgitation at Time of Left Ventricular Assist Device Implantation - Comparison of Systematic Mitral Valve Repair vs Surgical Abstention

Fifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients James K. Kirklin, MD, David C. Naftel,

Survival on the Heart Transplant Waiting List: Impact of Continuous Flow Left Ventricular Assist Device as Bridge to Transplant Jaimin R. Trivedi, MD,

The American Association for Thoracic Surgery 2016 Ethics Forum: Cost-effectiveness and the ethics of left ventricular assist device therapy John W.C.

Shinichi Fukuhara, MD, Koji Takeda, MD, PhD, Paul A

Pump Replacement for Left Ventricular Assist Device Failure Can Be Done Safely and Is Associated With Low Mortality Nader Moazami, MD, Carmelo A. Milano,

Douglas L. Mann, MD, Spencer H. Kubo, MD, Hani N

Left ventricular assist devices decrease fixed pulmonary hypertension in cardiac transplant candidates Daniel Zimpfer, MD, Philipp Zrunek, MS, Wilfried.

Video-Assisted Thoracoscopic Left Ventricular Pacing in Patients With and Without Previous Sternotomy Katharine E. Nelson, MBBS, MRCP, Matthew G.D. Bates,

New anticoagulant coatings and hemostasis assessment tools to avoid complications with pediatric left ventricular assist devices Daniel C. Leslie, PhD,

Surgical therapy for ischemic heart failure: Single-center experience with surgical anterior ventricular restoration Lorenzo Menicanti, MD, Serenella.

Effects on pre- and posttransplant pulmonary hemodynamics in patients with continuous-flow left ventricular assist devices Ranjit John, MD, Kenneth Liao,

Elucidating the intricate mechanisms of gastrointestinal bleeding in a continuous-flow left ventricular assist device will lead to future therapeutic.

The Impact of Prior Heart Failure Hospitalizations on Long-term Mortality Differs by Baseline Risk of Death Naga V.A. Kommuri, MD, Todd M. Koelling,

Surgical Ventricular Restoration for Advanced Congestive Heart Failure: Should Pulmonary Hypertension Be a Contraindication? Nishant D. Patel, BA, Jason.

Long-term mechanical circulatory support (destination therapy): On track to compete with heart transplantation? James K. Kirklin, MD, David C. Naftel,

Photodynamic Therapy for Early Stage Central Type of Lung Cancer

Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: Incidence, risk factors, and effect on outcomes

Risk Stratification and Interventional Cardiology: Robert L

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Outcomes after implantation of partial-support left ventricular assist devices in inotropic- dependent patients: Do we still need full-support assist devices?

Competing risks need to be considered in survival analysis models for cardiovascular outcomes Marianne Huebner, PhD, Martin Wolkewitz, Dr Sc Hum, Maurice.

The effect of coronary artery bypass grafting on specific causes of long-term mortality in the Bypass Angioplasty Revascularization Investigation David.

Cost-effectiveness of left ventricular assist devices (LVADs) for patients with advanced heart failure: Analysis of the British NHS bridge to transplant.

Does the degree of preoperative mitral regurgitation predict survival or the need for mitral valve repair or replacement in patients with anomalous origin.

Discussions in Cardiothoracic Treatment and Care: Mechanical Circulatory Support Left Ventricular Assist Device Therapy for Patients With Advanced Heart.

Should Patients 60 Years and Older Undergo Bridge to Transplantation With Continuous-Flow Left Ventricular Assist Devices? Jeremiah G. Allen, MD, Arman.

Outcomes on Continuous Flow Left Ventricular Assist Devices: A Single Institutional 9- Year Experience Jeffrey A. Morgan, MD, Pauline H. Go, MD, Linnea.

Durability of left ventricular assist devices: Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) 2006 to 2011 William L.

Posttransplant Outcomes Among Septuagenarians Bridged to Transplantation With Continuous-Flow Left Ventricular Assist Devices Shinichi Fukuhara, MD,

Mechanical Circulatory Support Pathways That Maximize Post-Heart Transplant Survival Tara Karamlou, MD, MS, Jill Gelow, MD, Brian S. Diggs, PhD, Frederick.

The use of mechanical circulatory support as a bridge to transplantation in pediatric patients: An analysis of the United Network for Organ Sharing database

Early Outcomes With Marginal Donor Hearts Compared With Left Ventricular Assist Device Support in Patients With Advanced Heart Failure Erin M. Schumer,

Predicting survival among high-risk pediatric cardiac transplant recipients: An analysis of the United Network for Organ Sharing database Ryan R. Davies,

Is severe right ventricular failure in left ventricular assist device recipients a risk factor for unsuccessful bridging to transplant and post-transplant.

Insertion of a left ventricular assist device in patients without thorough transplant evaluations: a worthwhile risk? Mathew Williams, MD, Jennifer Casher,

Jeffrey H. Shuhaiber, MD, Jeff Moore, MS, David B. Dyke, MD

Postcardiac transplant survival in the current era in patients receiving continuous-flow left ventricular assist devices Forum Kamdar, MD, Ranjit John,

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

The Journal of Thoracic and Cardiovascular Surgery

Current Status of Left Ventricular Assist Device Therapy

Prediction in idiopathic membranous nephropathy

Optimal timing for heart transplantation in patients bridged with left ventricular assist devices: Is timing of the essence? Chase R. Brown, MD, Fabliha.

Late Aortic Insufficiency Related to Poor Prognosis During Left Ventricular Assist Device Support Koichi Toda, MD, PhD, Tomoyuki Fujita, MD, Keitaro.

Creation of a Quantitative Score to Predict the Need for Mechanical Support in Children Awaiting Heart Transplant Ryan R. Davies, MD, Shylah Haldeman,

Daisuke Yoshioka, MD, Hiroo Takayama, MD, Arthur R. Garan, MD, Veli K

Marginal Donor Use in Patients Undergoing Heart Transplantation With Left Ventricular Assist Device Explantation Marat Fudim, MD, Mary E. Davis, MS,

Presentation transcript:

Can the Seattle Heart Failure Model Be Used to Risk-stratify Heart Failure Patients for Potential Left Ventricular Assist Device Therapy? Wayne C. Levy, MD, Dariush Mozaffarian, MD, DrPH, David T. Linker, MD, David J. Farrar, PhD, Leslie W. Miller, MD The Journal of Heart and Lung Transplantation Volume 28, Issue 3, Pages 231-236 (March 2009) DOI: 10.1016/j.healun.2008.12.015 Copyright © 2009 International Society for Heart and Lung Transplantation Terms and Conditions

Figure 1 The Seattle Heart Failure Score (SHFS) for patients in the original Seattle Heart Failure Model cohort are rounded to the closest integer from 0 to 4 and stratified by NYHA class. Within each NYHA class, the SHFS provided additional risk stratification. For any given SHFS, the risk of death was similar for NYHA Class II, III or IV heart failure patients. The percent of patients with SHFS 3 or 4 (>40% annual mortality) is shown for each NYHA class. The Journal of Heart and Lung Transplantation 2009 28, 231-236DOI: (10.1016/j.healun.2008.12.015) Copyright © 2009 International Society for Heart and Lung Transplantation Terms and Conditions

Figure 2 The number of REMATCH patients in each 10% grouping of 1-year survival with medical therapy as estimated by the Seattle Heart Failure Model. The Journal of Heart and Lung Transplantation 2009 28, 231-236DOI: (10.1016/j.healun.2008.12.015) Copyright © 2009 International Society for Heart and Lung Transplantation Terms and Conditions

Figure 3 Kaplan–Meier survival curve with the Seattle Heart Failure Score assuming medical management is rounded to the nearest integer from 3 to 5. (a) Survival in the medical group. (b) Survival in the LVAD group, which improved. The Journal of Heart and Lung Transplantation 2009 28, 231-236DOI: (10.1016/j.healun.2008.12.015) Copyright © 2009 International Society for Heart and Lung Transplantation Terms and Conditions

Figure 4 Kaplan–Meier survival curves for the LVAD and medical groups stratified by (a) high-, (b) moderate- and (c) low-risk tertiles of the Seattle Heart Failure Score. The Journal of Heart and Lung Transplantation 2009 28, 231-236DOI: (10.1016/j.healun.2008.12.015) Copyright © 2009 International Society for Heart and Lung Transplantation Terms and Conditions